Ocrelizumab: A Review in Multiple Sclerosis.

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Multiple Sclerosis (MS) encompasses relapsing (RMS) and primary progressive (PPMS) forms, posing significant challenges in treatment.
• Current therapeutic options aim to manage disease activity and progression.

Purpose of the Study:

• To evaluate the efficacy and safety of ocrelizumab, a humanized anti-CD20 monoclonal antibody, in treating adults with RMS and PPMS.
• To assess the long-term clinical benefits and safety profile of ocrelizumab.

Main Methods:

• Analysis of pivotal trials comparing ocrelizumab to interferon β-1a in RMS.
• Evaluation of single-arm studies in RMS subpopulations and placebo-controlled trials in PPMS.
• Assessment of clinical and MRI progression measures over ≥ 7.5 years of treatment.

Main Results:

• Ocrelizumab significantly reduced relapse rates and disease activity in RMS patients.
• Ocrelizumab demonstrated a reduction in clinical and MRI progression in PPMS patients compared to placebo.
• Long-term treatment maintained clinical benefits with a generally well-tolerated safety profile, consistent with clinical trial data.

Conclusions:

• Ocrelizumab is a highly effective and well-tolerated disease-modifying therapy for RMS.
• Ocrelizumab offers a valuable treatment option for delaying disease progression in PPMS, where approved alternatives are limited.
• The convenient, half-yearly infusion schedule enhances patient compliance and treatment experience.